Regulated Too Late: How the EPA's Prolonged Chemical Safety Process Leaves Americans Exposed for Generations

In the American regulatory imagination, the Environmental Protection Agency functions as a sentinel — an institution positioned to intercept dangerous chemicals before they accumulate in bodies, watersheds, and soil. The institutional reality is considerably less reassuring. The EPA's chemical risk assessment framework, governed principally by the Toxic Substances Control Act (TSCA) as amended by the Frank R. Lautenberg Chemical Safety for the 21st Century Act of 2016, routinely requires a decade or more to move a substance from initial hazard identification to enforceable restriction. During that interval, exposure continues largely unimpeded.

This is not a bureaucratic accident. It is, in meaningful respects, a structural feature of American chemical governance — one with measurable consequences for population health and one that peer-reviewed environmental health literature has documented with increasing specificity.

The Architecture of Delay

Under the TSCA framework, the EPA is required to evaluate high-priority chemicals through a multi-stage process encompassing hazard identification, dose-response assessment, exposure analysis, and risk characterization before any restriction can be proposed. Each stage generates public comment periods, industry submissions, interagency review, and, frequently, litigation. The agency must also demonstrate that its final rule represents the "least burdensome" approach to risk management — a statutory requirement that critics have long argued tilts the evidentiary burden away from protection and toward accommodation of commercial interests.

The 2016 Lautenberg amendments were intended to accelerate this process, establishing timelines for the evaluation of existing chemicals and eliminating certain barriers that had effectively paralyzed TSCA enforcement for decades. Progress has been real but uneven. As of 2024, the EPA has finalized risk evaluations for only a fraction of the chemicals it identified as high-priority following the amendments' passage, and several completed evaluations have faced legal challenge before risk management rules could take effect.

The consequence is a prolonged regulatory limbo in which a substance may be formally under evaluation — and therefore nominally subject to institutional scrutiny — while remaining in unrestricted commercial circulation for years or decades.

Case Studies in Cumulative Harm

The historical record provides instructive illustrations of how this timeline translates into public health burden.

Trichloroethylene (TCE), a solvent used extensively in metal degreasing and dry-cleaning operations, was identified as a probable human carcinogen by the International Agency for Research on Cancer in 1995. The EPA's own risk assessment, initiated years prior, was revised repeatedly across administrations before a final determination of carcinogenicity was published in 2011. A proposed rule to restrict occupational and consumer uses was not finalized until 2023 — nearly three decades after international scientific consensus had coalesced around the substance's hazard profile. Studies published in peer-reviewed toxicological journals have associated TCE exposure with elevated rates of kidney cancer, non-Hodgkin lymphoma, and Parkinson's disease. Communities near contaminated industrial sites, disproportionately lower-income and minority populations, bore the cumulative burden of that regulatory interval.

A parallel trajectory is observable with per- and polyfluoroalkyl substances (PFAS), a class of synthetic chemicals used in non-stick cookware coatings, food packaging, firefighting foam, and water-resistant textiles. Scientific concern about the persistence and bioaccumulation potential of PFAS compounds emerged in published literature during the late 1990s. Voluntary phase-outs of specific long-chain variants were negotiated with manufacturers in the mid-2000s, but comprehensive regulatory action under TSCA did not materialize for another decade and a half. In the interim, the compounds migrated into drinking water supplies serving hundreds of communities across the United States, with epidemiological research linking exposure to thyroid disease, immune dysfunction, and certain malignancies. The EPA's 2024 maximum contaminant level rules for several PFAS compounds in drinking water represent a significant policy milestone — but one arriving long after widespread population exposure had occurred.

The Precautionary Contrast

The European Union's chemical regulatory framework, governed by the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation, operates from a structurally different premise. Under REACH, the burden of demonstrating safety rests with manufacturers and importers before a substance enters the market in significant quantities. Substances of very high concern — including those that are carcinogenic, mutagenic, or persistent bioaccumulative toxicants — are subject to authorization requirements that effectively restrict use unless alternatives are unavailable and risks are demonstrably controlled.

This precautionary orientation does not eliminate all regulatory delay, nor does it produce perfect outcomes. Industry compliance costs are substantial, and certain restrictions have been contested on scientific grounds. Nevertheless, comparative analyses published in environmental health policy literature consistently find that the REACH framework generates restrictions on hazardous substances more rapidly than the TSCA process, and that European populations exhibit lower blood serum concentrations of several regulated compounds than their American counterparts.

Canada's approach under the Canadian Environmental Protection Act similarly incorporates precautionary language and has, in several instances, produced restrictions on substances — including certain flame retardants and phthalates — years before analogous EPA action.

Institutional Constraints and Political Economy

Attributing EPA delays solely to statutory design would be incomplete. The agency operates within a political economy that has historically favored industry consultation, and its rulemaking processes are vulnerable to administrative deceleration during administrations skeptical of regulatory expansion. Risk evaluations completed under one administration have been revisited or delayed under subsequent ones, introducing a temporal instability that compounds the underlying structural slowness of the TSCA process.

Funding constraints also bear examination. The EPA's chemical safety programs are chronically under-resourced relative to the volume of substances requiring evaluation. The agency is responsible for assessing thousands of chemicals already in commerce, a task that existing staffing and budget allocations cannot accomplish at a pace commensurate with the scale of potential public health risk.

Toward a More Protective Framework

Scholarship in health policy and environmental law has proposed several reforms with empirical grounding. First, eliminating or significantly revising the "least burdensome" requirement in TSCA's risk management provisions would recalibrate the evidentiary standard toward protection rather than commercial accommodation. Second, establishing a provisional restriction mechanism — analogous to the European Commission's ability to impose interim measures while full assessment proceeds — would reduce exposure during the evaluation period. Third, substantially increasing the EPA's chemical safety budget and statutory evaluation timelines would address the resource-driven delays that compound structural ones.

None of these reforms is politically uncomplicated. Each would encounter resistance from chemical industry stakeholders with well-organized lobbying capacity. But the public health literature is consistent: the current timeline between hazard identification and enforceable restriction represents an interval during which preventable harm accumulates in American bodies and communities.

The question the evidence compels is not whether regulatory delay has public health consequences. That relationship is documented. The operative question is whether American policymakers and the public are prepared to treat that delay as the policy failure it demonstrably is — and to accept the institutional redesign necessary to address it.